Osaic Holdings’s TScan Therapeutics TCRX Stock Holding History

Osaic Holdings’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12K	Buy	12,245 +2,489	+26%	+$2.65K	﹤0.01%	6507
2026 Q1	$9.85K	Sell	9,756 -2,489	-20%	-$2.66K	﹤0.01%	6299
2025 Q4	$12.2K	Hold	12,245	–	–	﹤0.01%	6211
2025 Q3	$21.9K	Hold	12,245	–	–	﹤0.01%	5869
2025 Q2	$17.8K	Sell	12,245 -2,489	-17%	-$3.6K	﹤0.01%	5802
2025 Q1	$20.3K	Buy	14,734 +2,489	+20%	+$5.38K	﹤0.01%	5359
2024 Q4	$37.2K	Hold	12,245	–	–	﹤0.01%	4912
2024 Q3	$61K	Hold	12,245	–	–	﹤0.01%	4600
2024 Q2	$71.6K	Buy	+12,245	New	+$96.4K	﹤0.01%	4394
2023 Q2	–	Sell	-1	Closed	-$2	–	7577
2023 Q1	$2	Buy	+1	New	+$2	﹤0.01%	7481

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Osaic Holdings's TCRX Position: Q2 2026 in Review

Osaic Holdings increased its TScan Therapeutics (TCRX) stake by 26% in Q2 2026, buying an estimated $2.65K and bringing the position to 12,245 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #6507.

Osaic Holdings first reported a position in TCRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $71.6K in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Osaic Holdings held 12,245 shares of TScan Therapeutics worth $12K as of Q2 2026.
Osaic Holdings bought 2,489 TScan Therapeutics shares in Q2 2026, an estimated $2.65K.
TScan Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6507 holding.
Osaic Holdings first reported a position in TScan Therapeutics in Q1 2023 and has held it in 10 quarters since.
Osaic Holdings's TScan Therapeutics position peaked at $71.6K in Q2 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.